Animal models of Alzheimer's disease and evaluation of anti-dementia drugs

Pharmacology and Therapeutics

Volumn 88, Issue 2, 2000, Pages 93-113

  Yamada, Kiyofumi ^a   Nabeshima, Toshitaka ^a  

^a NAGOYA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

Alzheimer's disease; Amyloid peptide (A ); Animal model; Presenilins; Tau; Amyloid precursor protein (APP)

Indexed keywords

ALPHA TOCOPHEROL; AMYLOID BETA PROTEIN; ANTIINFLAMMATORY AGENT; ANTIOXIDANT; APOLIPOPROTEIN E; ARGIPRESSIN; CHOLINERGIC RECEPTOR STIMULATING AGENT; CHOLINESTERASE INHIBITOR; CORTICOSTEROID; DONEPEZIL; ESTROGEN; IDEBENONE; MONOAMINE OXIDASE B INHIBITOR; NEFIRACETAM; NONSTEROID ANTIINFLAMMATORY AGENT; NOOTROPIC AGENT; PRESENILIN 1; PRESENILIN 2; PROPENTOFYLLINE; RIVASTIGMINE; SELEGILINE; TACRINE; TAU PROTEIN;

ALZHEIMER DISEASE; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; COGNITION; COGNITIVE DEFECT; CONTROLLED STUDY; DEMENTIA; NEUROFIBRILLARY TANGLE; NEUROPATHOLOGY; NONHUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL; RISK FACTOR; SENILE PLAQUE;

EID: 0034524088     PISSN: 01637258     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0163-7258(00)00081-4     Document Type: Review

References (281)

1. Fibrillogenesis of β-amyloid
2. Acetylcholinesterase promotes the aggregation of the amyloid-β-peptide fragments by forming a complex with the growing fibrils
3. Stable complexes involving acetylcholinesterase and amyloid-β peptide change the biochemical properties of the enzyme and increase the neurotoxicity of Alzheimer's fibrils
4. Reduced cerebrospinal fluid levels of α-secretase-cleaved amyloid precursor protein in aged rats: Correlation with spatial memory deficits
5. Exact cleavage site of Alzheimer amyloid precursor protein in neuronal PC12 cell
6. In vivo phosphorylation in the rat basal nucleus induces PHF-like and APP immunoreactivity
7. Paired helical filament-like phosphorylation of tau, deposition of β/A4-amyloid and memory impairment in rat induced by chronic inhibition of phosphatase 1 and 2A
8. Neurofibrillary tangles but not senile plaques parallel duration and severity of Alzheimer's disease
9. β-Amyloid peptides as direct cholinergic neuromodulators: A missing link?
10. Lack of apolipoprotein E dramatically reduces amyloid β-peptide deposition
11. Human presenilin-1, but not familial Alzheimer's disease (FAD) mutants, facilitate Caenorhabditis elegans Notch, signalling independently of proteolytic processing
12. Vitamin E protects nerve cells from amyloid β protein toxicity
13. Hydrogen peroxide mediates amyloid β protein toxicity
14. Simulation of cortical cholinergic deficits - A novel experimental approach to study pathogenetic aspects of Alzheimer's disease
15. Alpha-2 macroglobulin is genetically associated with Alzheimer's disease
16. The association between quantitative measures of dementia and senile change in the cerebral grey matter of elderly subjects
17. Familial Alzheimer's disease-linked presenilin 1 variants elevate Aβ1-42/1-40 ratio in vitro and in vivo
18. Accelerated amyloid deposition in the brains of transgenic mice coexpressing mutant presenilin 1 and amyloid precursor proteins
19. Tau phosphorylation in transgenic mice expressing glycogen synthase kinase 3β transgenes
20. Generation of β-amyloid in the secretory pathway in neuronal and non-neuronal cells
21. β-Amyloid fibrils induce tau phosphorylation and loss of microtubule binding
22. β-Amyloid peptide free radical fragments initiate synaptosomal lipoperoxidation in a sequence-specific fashion: Implications to Alzheimer's disease
23. Release of excess amyloid β protein from a mutant amyloid β protein precursor
24. Amyloid plaques and neuron death in APP transgenic mice
25. Roles for proteolysis and trafficking in Notch maturation and signal transduction
26. Early-onset Alzheimer's disease caused by mutations at codon 717 of β-amyloid precursor protein gene
27. The neurochemical and behavioral effects of β-amyloid peptide (25-35)
28. Transgenic mice with Alzheimer presenilin 1 mutations show accelerated neurodegeneration without amyloid plaque formation
29. Mutation of the β-amyloid precursor protein in familial Alzheimer's disease increases β-protein production
30. Mutant presenilins of Alzheimer's disease increase production of 42-residue amyloid β-protein in both transfected cells and transgenic mice
31. Implants containing β-amyloid protein are not neurotoxic to young and old rat brain
32. Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer's disease in late-onset families
33. Apolipoprotein E type 2 allele decreases the risk of late-onset Alzheimer's disease
34. Alzheimer's disease: A disorder of central cholinergic innervation
35. Block of LTP in rat hippocampus in vivo by β-amyloid precursor protein fragment
36. Association between Alzheimer's disease and NOS3 gene
37. Age-related cognitive deficits, impaired long-term potentiation and reduction in synaptic marker density in mice lacking the β-amyloid precursor protein
38. Deficiency of presenilin-1 inhibits the normal cleavage of amyloid precursor protein
39. A presenilin-1-dependent γ-secretase-like protease mediates release of Notch intracellular domain
40. Increased amyloid-β 42(43) in brains of mice expressing mutant presenilin 1
41. Activation of the L-voltage-sensitive calcium channel by mitogen-activated protein (MAP) kinase following exposure of neuronal cells to β-amyloid
42. Scavenger receptor-mediated adhesion of microglia to β-amyloid fibrils
43. Cleavage of amyloid peptide during constitutive processing of its precursor
44. Prevalence of Alzheimer's disease in a community population of older persons
45. Amnestic effects in mice of four synthetic peptides homologous to amyloid β protein from patients with Alzheimer's disease
46. Topography of a binding site for small amnestic peptides deduced from structure-activity studies: Relation to amnestic effect of amyloid β protein
47. Apoptosis mediated neurotoxicity induced by chronic application of β amyloid fragment 25-35
48. Ionic effects of the Alzheimer's disease β-amyloid precursor protein and its metabolic fragments
49. Effects of injected Alzheimer β-amyloid cores in rat brain
50. Protease inhibitor coinfusion with amyloid β-protein results in enhanced deposition and toxicity in rat brain
51. Microglial response to amyloid plaques in APPsw transgenic mice
52. Age-related spatial reference and working memory deficits assessed in the water maze
53. Effects of repeated administration of propentofylline on memory impairment produced by basal forebrain lesion in rats
54. Lack of Alzheimer pathology after β-amyloid protein injections in rat brain
55. Alzheimer-type neuropathology in transgenic mice overexpressing V717F β-amyloid precursor protein
56. Aging renders the brain vulnerable to amyloid β-protein neurotoxicity
57. Down patients: Extracellular preamyloid deposits precede neurite degeneration and senile plaques
58. From molecular structure to Alzheimer therapy
59. Similarities between β amyloid peptides 1-40 and 40-1: Effects on aggregation, toxicity in vitro, and injection in young and aged rats
60. Differential effects of amyloid peptides β(1-40) and β(25-35) injections into the rat nucleus basalis
61. Specific domains of β-amyloid from Alzheimer plaques elicit neuron killing in human microglia
62. The HHQK domain of β-amyloid provides a structural basis for the immunopathology of Alzheimer's disease
63. Alzheimer's disease: Its proteins and genes
64. Alzheimer's disease: Initial report of the purification and characterization of a novel cerebrovascular amyloid protein
65. Segregation of a missense mutation in the amyloid precursor protein gene with familial Alzheimer's disease
66. Characterization and chromosomal localization of a cDNA encoding brain amyloid of Alzheimer's disease
67. Somatodendritic localization and hyperphosphorylation of tau protein in transgenic mice expressing the longest human brain tau isoform
68. Amyloid β protein (Aβ) in Alzheimer's disease brain
69. Abnormal phosphorylation of the microtubule-associated protein tau in Alzheimer cytoskeletal pathology
70. Progress toward valid transgenic mouse models for Alzheimer's disease
71. Long-term treatment of Alzheimer's disease with idebenone
72. Amyloid β-peptide is produced by cultured cells during normal metabolism
73. β-Amyloid and a 3-kDa fragment are derived by distinct cellular mechanisms
74. Amyloid, the presenilins and Alzheimer's disease
75. Alzheimer's disease: The amyloid cascade hypothesis
76. Genetic dissection of Alzheimer's disease and related dementias: Amyloid and its relationship to tau
77. 24)25-35 in rat nucleus basalis induces behavioral dysfunctions, impairs learning and memory and disrupts cortical cholinergic innervation
78. Propionyl-IIGL tetrapeptide antagonizes β-amyloid excitotoxicity in rat nucleus basalis
79. Presenile dementia and cerebral hemorrhage linked to a mutation at codon 692 of the β-amyloid precursor protein gene
80. Transgenic mouse brain histopathology resembles early Alzheimer's disease
81. Accelerated Alzheimer-type phenotype in transgenic mice carrying both mutant amyloid precursor protein and presenilin 1 transgenes
82. Behavioral changes in transgenic mice expressing both amyloid precursor protein and presenilin-1 mutations: Lack of association with amyloid deposits
83. Regulation of mitochondrial pyruvate dehydrogenase activity by tau protein kinase I/glycogen synthase kinase 3β in brain
84. Nontoxic amyloid β peptide 1-42 suppresses acetylcholine synthesis
85. Common structural features determine the effectiveness of carvedilol, daunomycin and rolitetracycline as inhibitors of Alzheimer β-amyloid fibril formation
86. Inhibition of fibril formation in β-amyloid by a novel series of benzofurans
87. Age-related CNS disorder and early death in transgenic FVB/N mice overexpressing Alzheimer amyloid precursor proteins
88. Correlative memory deficits, Aβ elevation, and amyloid plaques in transgenic mice
89. Identification of a novel aspartic protease (Asp 2) as β-secretase
90. Association of missense and 5′-splice site mutations in tau with the inherited dementia FTDP-17
91. Acetylcholinesterase accelerates assembly of amyloid-β-peptides into Alzheimer's fibrils: Possible role of the peripheral site of the enzyme
92. APPsw transgenic mice develop age-related Aβ deposits and neutrophil abnormalities, but no neuronal loss in CA1
93. Aβ deposition is associated with neutrophil changes, but not with overt neuronal loss in the human precursor protein V717F (PDAPP) transgenic mouse
94. Dysfunction of cholinergic and dopaminergic neuronal systems in β-amyloid protein-infused rats
95. Effects of metrifonate on memory impairment and cholinergic dysfunction in rats
96. Impairment of long-term potentiation in hippocampal slices of β-amyloid-infused rats
97. Visualization of Aβ42(43) and Aβ40 in senile plaques with end-specific Aβ monoclonals: Evidence that an initially deposited species is Aβ42(43)
98. Neurodegenerative changes including altered tau phosphorylation and neurofilament immunoreactivity in mice transgenic for the serine/threonine kinase Mos
99. Seeding "one-dimensional crystallization" of amyloid: A pathogenic mechanism in Alzheimer's disease and scrapie?
100. Cerebrospinal fluid Aβ42 is increased early in sporadic Alzheimer's disease and declines with disease progression
101. Continuous exposure to β-amyloid protein influences glutathione homeostasis in the rat brain
102. Amyloid precursor protein processing and Aβ42 deposition in a transgenic mouse model of Alzheimer disease
103. Regulation of amyloid precursor protein secretion by glutamate receptors in human Ntera 2 neurons (NT2N)
104. Deposition of β/A4 immunoreactivity and neuronal pathology in transgenic mice expressing the carboxy-terminal fragment of the Alzheimer amyloid precursor in the brain
105. The precursor of Alzheimer's disease amyloid A4 protein resembles a cell surface receptor
106. β-Amyloid-related peptides inhibit potassium-evoked acetylcholine release from rat hippocampal formation
107. Amyloid β-peptide inhibits high-affinity choline uptake and acetylcholine release in rat hippocampal slices
108. Advances in Alzheimer's disease
109. Amyloid β-peptide disrupts carbachol-induced muscarinic cholinergic signal transduction in cortical neurons
110. Effects of vinconate on spatial learning impairments induced by medial septal lesion in rats
111. Arresting amyloidosis in vivo using small molecule anionic sulphonates or sulphates: Implications for Alzheimer's disease
112. Novel precursor of Alzheimer's disease amyloid protein shows protease inhibitory activity
113. β-Amyloid protein increases the vulnerability of cultured cortical neurons to excitotoxic damage
114. Microtubule-associated protein tau is a major antigenic component of paired helical filaments in Alzheimer disease
115. An in vivo model for the neurodegenerative effects of β-amyloid and protection by substance P
116. The Alzheimer's Aβ peptide induces neurodegeneration and apoptotic cell death in transgenic mice
117. Altered metabolism of familial Alzheimer's disease-linked amyloid precursor protein variants in yeast artificial chromosome transgenic mice
118. Diffusible, nonfibrillar ligands derived from Aβ1-42 are potent central nervous system neurotoxins
119. Structural model for the β amyloid fibril: Interstrand alignment of an antiparallel β sheet comprising a C-terminal peptide
120. 2+]I in rat astrocytes
121. Facilitation of lin-12-mediated signalling by sel-12, a Caenorhabditis elegans S182 Alzheimer's disease gene
122. Assessment of normal and mutant presenilin function in Caenorhabditis elegans
123. Mutation of the Alzheimer's disease amyloid gene in hereditary cerebral hemorrhage, Dutch type
124. Candidate gene for the chromosome 1 familial Alzheimer's disease locus
125. Apoptosis is induced by β-amyloid in cultured central nervous system neurons
126. β-Amyloid neurotoxicity requires fibril formation and is inhibited by Congo red
127. The phosphorylation of tau: A critical stage in neurodevelopment and neurodegenerative processes
128. The prolyl isomerase Pin 1 restores the function of Alzheimer-associated phosphorylated tau protein
129. Amyloid-associated proteins α1-antichymotrypsin and apolipoprotein E promote assembly of Alzheimer β-protein into filaments
130. Tau in Alzheimer's disease
131. The pattern of acquisition of plaques and tangles in the brains of patients under 50 years of age with Down's syndrome
132. A 12-month, randomized, placebo-controlled trial of propentofylline (HWA285) in patients with dementia according to DMSIII-R
133. Oxidative stress hypothesis in Alzheimer's disease
134. Amyloid plaque core protein in Alzheimer disease and down syndrome
135. Cellular actions of β-amyloid precursor protein and its soluble and fibrillogenic derivatives
136. β-Amyloid peptides destabilize calcium homeostasis and render human cortical neurons vulnerable to excitotoxicity
137. Neuroprotective and anti-amnesic potentials of sigma (σ) receptor ligands
138. Amnesia induced by centrally administered β-amyloid peptides involves cholinergic dysfunction
139. Sigma1 (σ1) receptor agonists and neurosteroids attenuates β25-35 amyloid peptide-induced amnesia in mice through a common mechanism
140. Present imperfect: A critical review of animal models of the mnemonic impairments in Alzheimer's disease
141. Effects of exogenous β-amyloid peptide on retention for spatial learning
142. The inflammatory response system of brain: Implications for therapy of Alzheimer and other neurodegenerative diseases
143. Anti-inflammatory agents as a therapeutic approach to Alzheimer's disease
144. Clinical diagnosis of Alzheimer's disease: Report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease
145. Activation of microglial cells by β-amyloid protein and interferon-γ
146. Proteolytic degradation of Alzheimer's disease amyloid β-peptide by a metalloproteinase from microglia cells
147. Interaction of anthracycline 4′-iodo-4′-deoxydoxorubicin with amyloid fibrils: Inhibition of amyloidogenesis
148. Memory-enhancing effects of secreted forms of the β-amyloid precursor protein in normal and amnestic mice
149. Regulation of amyloid precursor protein cleavage
150. Learning deficits induced by chronic intraventricular infusion of quinolinic acid protection by MK-801 and memantine
151. Cholesterol-dependent generation of a seeding amyloid β-protein in cell culture
152. Differential effects of apolipoprotein E isoforms on metal-induced aggregation of Aβ using physiological concentrations
153. Age-related learning deficits in transgenic mice expressing the 751-amino acid isoform of human β-amyloid precursor protein
154. Co-injection of β-amyloid with ibotenic acid induces synergistic loss of rat hippocampal neurons
155. Ibotenate lesions of hippocampus and/or subiculum: Dissociating components of allocentric spatial learning
156. Age-related changes in the density and morphology of plaques and neurofibrillary tangles in Down syndrome brain
157. Using okadaic acid as a tool for the in vivo induction of hyperphosphorylated tau
158. A pathogenic mutation for probable Alzheimer's disease in the APP gene at the N-terminus of β-amyloid
159. Pilocarpine and physostigmine attenuate spatial memory impairments produced by lesions of the nucleus basalis magnocellularis
160. A mutation in the amyloid precursor protein associated with hereditary Alzheimer's disease
161. Behavioral aspects of cholinergic transmission: Role for basal forebrain cholinergic system in learning and memory
162. Ameliorating effects of nefiracetam (DM-9384) on brain dysfunction
163. Toxicity of β-amyloid protein: Neurochemical, histological and behavioral changes
164. Alzheimer's disease animal models induced by continuous infusion of β-amyloid protein and anti-nerve growth factor antibody
165. Memory impairment and neuronal dysfunction induced by β-amyloid protein in rats
166. New therapeutic approaches to Alzheimer's disease
167. Memory impairment and morphological changes in rats induced by active fragment of anti-nerve growth factor antibody
168. Oral administration of NGF synthesis stimulators recovers reduced brain NGF content in aged rats and cognitive dysfunction in basal-forebrain-lesioned rats
169. Accumulation of murine amyloid β42 in a gene-dosage-dependent manner in PS1 'knock-in' mice
170. Impaired learning and LTP in mice expressing the carboxy terminus of the Alzheimer amyloid precursor protein
171. Apolipoprotein E immunoreactivity in cerebral amyloid deposits and neurofibrillary tangles in Alzheimer's disease and kuru plaque amyloid in Creutzfeldt-Jakob disease
172. Missense mutation of Val→Ile in exon 17 of amyloid precursor protein gene in Japanese familial Alzheimer's disease
173. Indomethacin reverses the microglial response to amyloid β-protein
174. Alzheimer's disease: A re-examination of the amyloid hypothesis
175. Release of Alzheimer amyloid precursor derivatives stimulated by activation of muscarinic acetylcholine receptors
176. Memory impairment and neural dysfunction after continuous infusion of anti-nerve growth factor antibody into the septum in adult rats
177. Effects of oral administration of a stimulator for nerve growth factor synthesis in basal forebrain-lesioned rats
178. β-Amyloid protein-induced Alzheimer's disease animal model
179. Oral administration of idebenone induces nerve growth factor in the brain and improves learning and memory in basal-forebrain-lesioned rats
180. Propentofylline prevents neuronal dysfunction induced by infusion of anti-nerve growth factor antibody into the rat septum
181. Continuous infusion of β-amyloid protein into cerebral ventricle induces learning impairment and neuronal and morphological degeneration
182. One of the antigenic determinants of paired helical filaments is related to tau protein
183. Naftidrofuryl oxalate, nootropic effects on the scopolamine- and the basal-forebrain-lesion-induced amnesia in rats
184. Endogenous GLP-1 modulates hippocampal activity in β-amyloid protein-treated rats
185. Alterations of nicotinic cholinergic receptor binding induced by beta-amyloid (1-42) in rats
186. Mutant presenilin 2 transgenic mouse: Effect on an age-dependent increase of amyloid β-protein 42 in the brain
187. Evidence of oxidative stress and in vivo neurotoxicity of β-amyloid in a transgenic mouse model of Alzheimer's disease. A chronic oxidative paradigm for testing antioxidant therapies in vivo
188. Microglial cells internalize aggregates of the Alzheimer's disease amyloid β-protein via a scavenger receptor
189. Amyloid β-peptides injection into the cholinergic nuclei: Morphological, neurochemical and behavioral effects
190. In vitro aging of β-amyloid protein causes peptide aggregation and neurotoxicity
191. Neurodegeneration induced by β-amyloid peptides in vitro: The role of peptide assembly state
192. Synthetic amyloid β-protein fails to produce specific neurotoxicity in monkey cerebral cortex
193. Microinjection of synthetic amyloid β-protein in monkey cerebral cortex fails to produce acute neurotoxicity
194. Apolipoprotein E in animal models of CNS injury and in Alzheimer's disease
195. A new A4 amyloid mRNA contains a domain homologous to serine proteinase inhibitors
196. Tau is a candidate gene for chromosome 17 frontotemporal dementia
197. Alzheimer's disease: Genetic studies and transgenic models
198. Degradation of amyloid β-protein by a metalloprotease secreted by microglia and other neural and non-neural cells
199. Formation of β-amyloid protein deposits in brains of transgenic mice
200. Rationalizing a pharmacological intervention on the amyloid precursor protein metabolism
201. Enhanced amyloidogenic processing of the β-amyloid precursor protein in gene targeted mice bearing the Swedish familial Alzheimer's disease mutations and a "humanized" Aβ sequence
202. Molecular cloning and characterization of a cDNA encoding the cerebrovascular and the neuritic plaque amyloid peptides
203. The regulation of amyloid precursor protein metabolism by cholinergic mechanisms and neurotrophin receptor signaling
204. Familial Alzheimer's disease in kindreds with missense mutations in a gene on chromosome 1 related to the Alzheimer's disease type 3 gene
205. The Alzheimer diseases
206. A controlled trial of selegiline, alpha-tocopherol, or both as treatment for Alzheimer's disease
207. Neurodegeneration and gliosis in transgenic mice overexpressing a carboxy-terminal fragment of Alzheimer amyloid-β protein precursor
208. Association of apolipoprotein E allele ε4 with late-onset familial and sporadic Alzheimer's disease
209. Immunization with amyloid-β attenuates Alzheimer-disease-like pathology in the PDAPP mouse
210. Secreted amyloid β-protein similar to that in the senile plaques of Alzheimer's disease is increased in vivo by the presenilin 1 and 2 and APP mutations linked to familial Alzheimer's disease
211. Increased amyloid β-peptide deposition in cerebral cortex as a consequence of apolipoprotein E genotype in late-onset Alzheimer disease
212. Amyloid peptides are toxic via a common oxidative mechanism
213. The cell biology of β-amyloid precursor protein and presenilin in Alzheimer's disease
214. Translating cell biology into therapeutic advances in Alzheimer's disease
215. Isolation and quantification of soluble Alzheimer's β-peptide from biological fluids
216. Secretion of β-amyloid precursor protein cleaved at the amino terminus of the β-amyloid peptide
217. Cloning of a gene bearing missense mutations in early-onset familial Alzheimer's disease
218. Bilateral injections of amyloid-β 25-35 into the amygdala of young Fischer rats: Behavioral, neurochemical, and time dependent histopathological effects
219. Role of estrogen replacement therapy in memory enhancement and prevention of neuronal loss associated with Alzheimer's disease
220. Purification and cloning of amyloid precursor protein β-secretase from human brain
221. Beta-amyloid precursor protein cleavage by a membrane bound protease
222. Evidence that β-amyloid protein in Alzheimer's disease is not derived by normal processing
223. Expression of an ubiquitous cross-homologue of the mouse β-amyloid precursor protein (APP)
224. Amyloid-β deposition in Alzheimer transgenic mice is associated with oxidative stress
225. An important role of heparan sulfate proteoglycan (perlecan) in a model system for the deposition and persistence of fibrillar Aβ-amyloid in rat brain
226. Inhibition of Alzheimer's amyloidosis by peptides that prevent β-sheet conformation
227. β-Sheet breaker peptides inhibit fibrillogenesis in a rat brain model of amyloidosis: Implications for Alzheimer's therapy
228. Tau protein pathology in neurodegenerative diseases
229. Mutation in the tau gene in familial multiple system tauopathy with presenile dementia
230. Apolipoprotein E: High-avidity binding to β-amyloid and increased frequency of type 4 allele in late-onset familial Alzheimer disease
231. Transgenic animals in Alzheimer's disease research
232. Two amyloid precursor protein transgenic mouse models with Alzheimer disease-like pathology
233. An increased percentage of long amyloid β protein secreted by familial amyloid β protein precursor (βAPP717) mutants
234. Intrahippocampal β-amyloid impairs win-shift radial maze performance in rats
235. Tau protein kinase I is essential for amyloid β-protein-induced neurotoxicity
236. NC-1900, an active fragment analog of arginine vasopressin, improves learning and memory deficits induced by β-amyloid protein in rats
237. Effects of oestrogen during menopause on risk and age at onset of Alzheimer's disease
238. The amyloid beta protein gene: cDNA cloning, mRNA distribution, and genetic linkage near the Alzheimer's locus
239. Protease inhibitor domain encoded by an amyloid protein precursor mRNA associated with Alzheimer's disease
240. Presence of soluble amyloid β-peptide precedes amyloid plaque formation in Down's syndrome
241. Physical basis of cognitive alterations in Alzheimer's disease: Synapse loss is the major correlate of cognitive impairment
242. Endoproteolysis of presenilin 1 and accumulation of processed derivatives in vivo
243. Arrest of β-amyloid fibril formation by a pentapeptide ligand
244. The presenilin 2 mutation (N141I) linked to familial Alzheimer disease (Volga German families) increases the secretion of amyloid β protein ending at the 42nd (43rd) residue
245. Molecular dissection of domains in mutant presenilin 2 that mediate overproduction of amyloidogenic forms of amyloid β peptides
246. Rifampicin inhibits the toxicity of pre-aggregated amyloid peptides by binding to peptide fibrils and preventing amyloid-cell interaction
247. Amyloid β protein precursor gene and hereditary cerebral hemorrhage with amyloidosis
248. Acute or chronic administration of okadaic acid to rats induces brain damage rather than Alzheimer-like neuropathology
249. β-Secretase cleavage of Alzheimer's amyloid precursor protein by the transmembrane aspartic protease BACE
250. Familial Alzheimer's disease: Oxidative stress, β-amyloid, presenilins and cell death
251. Solvent effects on beta protein toxicity in vivo
252. 192IgG-saporin
253. 192Immunoglobulin G-saporin produces graded behavioral and biochemical changes accompanying the loss of cholinergic neurons of the basal forebrain and cerebellar Purkinje cells
254. Dephosphorylation of Alzheimer paired helical filaments by protein phosphatase-2A and -2B
255. Identification of a mouse brain cDNA that encodes a protein related to the Alzheimer disease-associated amyloid β protein precursor
256. Identification, biogenesis, and localization of precursors of Alzheimer's disease A4 amyloid protein
257. 2+ channel blockers attenuate β-amyloid peptide toxicity to cortical neurons in culture
258. Fibrillar β-amyloid induces microglial phagocytosis, expression of inducible nitric oxide synthase, and loss of a selected population of neurons in rat CNS in vivo
259. Neural lesioning with ribosome-inactivating proteins: Suicide transport and immunolesioning
260. Immunolesioning: Selective destruction of neurons using immunotoxin to rat NGF receptor
261. Cholinergic strategies for Alzheimer's disease
262. Acceleration of Alzheimer's fibril formation by apolipoprotein E in vitro
263. Two transmembrane aspartates in presenilin-1 required for presenilin endoproteolysis and γ-secretase activity
264. Neurofibrillary tangles of Alzheimer disease share antigenic determinants with the axonal microtubule-associated protein tau
265. β-Amyloid (1-40) increases long-term potentiation in rat hippocampus in vitro
266. Nefiracetam (DM-9384): A novel anti-amnesic drug
267. Neurotoxicity induced by continuous infusion of quinolinic acid into the lateral ventricle in rats
268. Impairment of active avoidance response in rats with continuous infusion of quinolinic acid into the lateral ventricle
269. Changes in ciliary neurotrophic factor content in the rat brain after continuous intracerebroventricular infusion of β-amyloid (1-40) protein
270. Orally active NGF synthesis stimulators: Potential therapeutic agents in Alzheimer's disease
271. Propentofylline improves learning and memory deficits in rats induced by β-amyloid protein (1-40)
272. Perspectives of pharmacotherapy in Alzheimer's disease
273. Protective effects of idebenone and α-tocopherol on β-amyloid (1-42)-induced learning and memory deficits in rats: Implication of oxidative stress in β-amyloid-induced neurotoxicity in vivo
274. Improvement by nefiracetam of β-amyloid (1-42)-induced learning and memory impairments in rats
275. Long-term deprivation of oestrogens by ovariectomy potentiates β-amyloid-induced working memory deficits in rats
276. Membrane-anchored aspartyl protease with Alzheimer's disease β-secretase activity
277. RAGE and amyloid-β peptide neurotoxicity in Alzheimer's disease
278. Mechanisms of neuronal degeneration in Alzheimer's disease
279. Neurotrophic and neurotoxic effects of amyloid β protein: Reversal by tachykinin neuropeptides
280. The 717Val→Ile substitution in amyloid precursor protein is associated with familial Alzheimer's disease regardless of ethnic groups
281. β-Amyloid precursor protein-deficient mice show reactive gliosis and decreased locomotor activity